Caxton Associates (New York)’s Relay Therapeutics RLAY Stock Holding History

Caxton Associates (New York)’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-107,568	Closed	-$701K	–	633
2024 Q2	$701K	Sell	107,568 -23,248	-18%	-$159K	0.02%	291
2024 Q1	$1.09M	Sell	130,816 -148,285	-53%	-$1.45M	0.06%	209
2023 Q4	$3.07M	Buy	279,101 +241,247	+637%	+$2.04M	0.16%	79
2023 Q3	$318K	Buy	+37,854	New	+$407K	0.04%	301

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Caxton Associates (New York)'s RLAY Position: Q3 2024 in Review

Caxton Associates (New York) sold out of Relay Therapeutics (RLAY) in Q3 2024, closing a stake of 107,568 shares — an estimated $701K sold.

Caxton Associates (New York) first reported a position in RLAY in Q3 2023 and held it in 4 quarters. The position peaked at $3.07M in Q4 2023. 195 funds tracked by Wall St. Rank hold RLAY as of Q3 2024.

Caxton Associates (New York) reported no remaining Relay Therapeutics position as of Q3 2024 after selling out during the quarter.
Caxton Associates (New York) sold 107,568 Relay Therapeutics shares in Q3 2024, an estimated $701K.
Caxton Associates (New York) first reported a position in Relay Therapeutics in Q3 2023 and held it in 4 quarters.
Caxton Associates (New York)'s Relay Therapeutics position peaked at $3.07M in Q4 2023.
195 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2024.

Based on Caxton Associates (New York)'s 13F filing for Q3 2024, filed 14 Nov 2024.